Adverum Biotechnologies faces a precarious financial outlook as it continues to prioritize high-cost clinical development programs despite a complete absence of recurring revenue. The company's rapid erosion of equity to a $55.7M deficit and a deteriorating cu...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Benchmark ADVM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Adverum Biotechnologies, Inc. (ADVM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.36 | $96.26M | -0.66 | -72.22% | -13092.7% | -189.84% | — | |
| $1.00 | $339.11M | -4.35 | 8.83% | -1786.27% | — | — | |
| $2.69 | $412.81M | -1.49 | 25.39% | -157.32% | -196.63% | — | |
| $341.75 | $10.07B | 49.96 | 33.94% | 54.82% | 19.34% | — | |
| $14.88 | $1.47B | -2.55 | 20.13% | -81.79% | — | — | |
| $62.21 | $12.02B | 34.56 | 12.87% | 2.14% | 1.18% | — |
Adverum Biotechnologies, Inc. (ADVM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when ADVM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Adverum Biotechnologies, Inc. (ADVM) stock FAQ — growth, dividends, profitability & financials explained
Adverum Biotechnologies, Inc. (ADVM) reported $1.0M in revenue for fiscal year 2024. This represents a 3233% increase from $0.0M in 2012.
Adverum Biotechnologies, Inc. (ADVM) saw revenue decline by 72.2% over the past year.
Adverum Biotechnologies, Inc. (ADVM) reported a net loss of $204.4M for fiscal year 2024.
Adverum Biotechnologies, Inc. (ADVM) has a return on equity (ROE) of -189.8%. Negative ROE indicates the company is unprofitable.
Adverum Biotechnologies, Inc. (ADVM) had negative free cash flow of $138.4M in fiscal year 2024, likely due to heavy capital investments.
